Press

HTGF portfolio company AYOXXA Biosystems wins new investors to close a € 9,0m Series B round

July 10, 2014

AYOXXA Biosystems GmbH, an international biotechnology company, completed a € 9,0m Series B financing round by the end of June 2014. All of the company’s existing investors (High-Tech Gründerfonds, KFW, NRW.BANK, Wellington Partners Venture Capital and private investors) took part, along with new investors b-to-v Partners AG, Creathor Venture and HR Ventures. In addition several private investors from the US and Europe, including AYOXXA employees and two of Qiagen’s founders, joined this financial round.

In line with the company’s strategy to commercialize its novel in-situ encoded bead array technology (IEBA), the funding will be used to scale-up the production of AYOXXA’s proprietary biochips as well as to achieve international commercial readiness. To celebrate this milestone, AYOXXA launched a fresh Corporate Identity (CI) seamlessly integrated into its website www.AYOXXA.com. AYOXXA now stands for “Leveraging success in proteomics”. “I am pleased that we were able to close this round in a macro- environment that currently is very challenging, finding funding for young companies has become extremely difficult.”, comments Dr. Andreas Schmidt, CEO of AYOXXA, “Beyond the financial assets, we will benefit from the expanded network in the biotechnology, pharmaceutical and enabling technology field. This will facilitate effective commercialization of our IEBA technology in the near future.” he adds.

“AYOXXA adds a new dimension to enabling research technologies. Its IP-protected new detection and evaluation multiplex-platform can be easily integrated into current workflows. I see a very high potential for such a novel approach to protein multiplex testing.” adds Prof. Riesner, one of the Qiagen founders and new AYOXXA investor. In order to complement the co-founders Dr. Andreas Schmidt (CEO) and Prof. Dieter Trau (CSO) AYOXXA attracts experienced leadership for its corporate executive management team and supervisory board:

Dr. Markus Zumbansen, Vice President Research and Development, has more than ten years of experience in the development of platform technologies. Before joining AYOXXA he worked in different R&D positions within the biotech industry, Miltenyi Biotec being his last station.

Michael Rasche, newly appointed Corporate Vice President Global Commercial Operations is now leading all activities in the area of marketing, sales and business development. He has an international background with 23 years of experience in leading Pharma- and Diagnostic-companies.

Rodney Turner, until recently Vice President of Corporate Business Development for Life Technologies Corporation, joins AYOXXA’s supervisory board as of immediately. Mr. Turner graduated with a BA from Rice University. He had a leading role in the acquisitions of AMG Advanced Microscopy Group, BAC The Bioaffinity Company, BioTrove, Stokes Bio, GeneArt AG, Ambion, and several others. His extensive experience in life science tools companies will primarily help to accelerate product introduction into new markets across the research segments.

About AYOXXA
AYOXXA Biosystems GmbH, an international biotech company based in Cologne (Germany) and Singapore, has developed a proprietary technology platform for multiplex protein analysis. Core to the cutting-edge system is a bead-based technology (IEBA) that yields 10,000-fold more data points than a standard 384-well ELISA. Together with lowest sample volume in the multiplex protein arena, an increased assay robustness, and readout with existing equipment, AYOXXA will bring a paradigm shift to biomedical research, pharmacological screening and preclinical diagnostics development.
www.ayoxxa.com

Contact:
Dr. Andreas Schmidt (CEO)
AYOXXA Biosystems GmbH
Nattermannallee 1
50829 Cologne
Phone:     +49 (0) 221 222529 10
info@ayoxxa.com

b-to-v Partners AG
www.b-to-v.com

Creathor Venture
www.creathor.de

HR Ventures
www.hr-ventures.com

KfW Bank
www.kfw.de/kfw.de-2.html

NRW.BANK
www.nrwbank.com/en/index.html

Wellington Partners Venture Capital
www.wellington-partners.com/wp/index.html

About High-Tech Gruenderfonds
High-Tech Gruenderfonds invests in young, high potential high-tech start-ups. The seed financing provided is designed to enable start-ups to take an idea through prototyping and to market launch. Typically, High-Tech Gruenderfonds invests EUR 500,000 in the seed stage, with the potential for up to a total of EUR 2 million per portfolio company in follow-on financing. Investors in this public/private partnership include the Federal Ministry of Economics and Energy, the KfW Banking Group, as well as strategic corporate investors including ALTANA, BASF, Bayer, B. Braun, Robert Bosch, CEWE, Daimler, Deutsche Post DHL, Deutsche Telekom, Evonik, Lanxess, media + more venture Beteiligungs GmbH & Co. KG, METRO, Qiagen, RWE Innogy, SAP, Tengelmann and Carl Zeiss. High-Tech Gruenderfonds has about EUR 576 million under management in two funds (EUR 272 million HTGF I, EUR 304 million HTGF II).

Contact:
High-Tech Gruenderfonds Management GmbH
Dr. Matthias Dill
Senior Investment Manager
Schlegelstrasse 2
D-53113 Bonn
Phone: +49 228 823001-00
Fax: +49 228 823000-50
info@htgf.de
www.high-tech-gruenderfonds.de

Stay up to date

Subscribe now and receive the latest press releases on investments and other news from High-Tech Gründerfonds. We inform you about important developments at HTGF and provide you with interesting news from our portfolio. Whether it’s a successful exit, a new exciting investment or HR news – you’ll be the first to know!

More Press posts

Press
25. March 2024

Successful exit for HTGF: Novo Nordisk to acquire Cardior Pharmaceuticals

Novo Nordisk will acquire Cardior for up to 1.025 billion Euros in upfront and potential milestone payments. Cardior is a leader in the discovery and development of therapies that target RNA as a means to prevent, repair and reverse diseases of the heart. High-Tech Gründerfonds (HTGF), one of Europe’s leading seed investors, participated in the first financing round in 2017. Bonn, Germany, 25 March 2024 – Novo Nordisk and Cardior Pharmaceuticals today announced that N
 
Press
25. March 2024

Growth push for CI HUB GmbH, Catalyzing Innovation in Content Integration Solutions

Potsdam, 25.03.2024 – Scale Capital, a Danish early stage technology investor with a focus on helping companies accelerate growth in the US market, has announced its investment in CI HUB GmbH, a leading provider of content integration solutions. This significant seven-figure amount from new and existing investors marks a milestone in CI HUB’s journey towards revolutionizing the way corporates and creatives access digital assets and data. CI HUB specializes in developing innovative
 
Press
20. March 2024

graswald.ai raises $3.3M seed round to scale the way brands create 3D content with AI

The Hannover-based start-up has secured seed funding to build Canva for 3D, leveraging generative AI to transform 3D creative processes for 3D product visualisation. Hannover, 20 March 2024 – graswald.ai announced the close of a $3.3 million seed round led by existing investor Lakestar as well as Supernode Global with continued support from existing investor HTGF and further participation from Spatial Computing expert FOV Ventures, Robin Capital, Angel Invest Ventures and Notion Sc